I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Psichiatria, Psicologia e Psicofarmacologia
Official Journal of the Italian Society of Social Psychiatry
Indexed/Abstracted in: EMBASE, e-psyche, PsycINFO, Scopus, Emerging Sources Citation Index
Minerva Psichiatrica 2016 Giugno;57(2):62-71
Alpha-glutathione-s-transferase can be a biomarker for both drug-related toxicity as well as individual susceptibility
Melda CİBA 1, Mehmet AK 2, Bensu KARAHALİL 1
1 Department of Toxicology, Faculty of Pharmacy, Gazi University, Ankara, Turkey; 2 Department of Psychiatry, Faculty of Medicine, Konya Necmettin Erbakan University, Konya, Turkey
BACKGROUND: Psychiatric disorders are health concern. The important issue is that the response of treatment of patients is different. Some patients are in remission, some suffer from adverse drug reactions (ADRs). Hepatic function is monitored by liver enzymes. It is important to detect liver injury and its evaluation according to the genetic polymorphisms in early phase of treatment. Alpha-glutathione-s-transferase (alpha-GST) is a sensitive biomarker compared to the liver enzymes. GSTs are phase II conjugation enzymes that detoxify xenobiotic and protect cells from the oxidative stress. GSTM1, GSTT1 and GSTP1 are polymorphic. Null genotypes cause lack of activity. Our aim was to investigate whether alpha-GST might be earlier biomarker than liver enzymes for liver injury and impact of individual susceptibility.
METHODS: Blood samples before treatment, 10±3 days and 3±1 months of treatments were taken from 132 psychotic disorder patients in treatment. Serum alpha-GST was measured by Enzyme Linked Immunosorbent Assay (ELISA) and GSTs gene polymorphisms were genotyped by Polymerase Chain Reaction.
RESULTS: Our data indicated that alpha-GST might be a biomarker for liver injury and GSTs gene polymorphisms had a contribution to the risk of psychotic disorders.
CONCLUSIONS: Our results encourage making research on finding more specific biomarker and individual susceptibility with larger sample size.